Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease.

Related Articles Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Singh S, Fumery M, Sandborn WJ, Murad MH Abstract BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn’s disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of…

Read More

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease.

Related Articles An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn’s disease. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V Abstract BACKGROUND: Fibrotic stricture is a common complication of Crohn’s disease (CD) affecting approximately half of all patients. No specific…

Read More

Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: A pilot study.

Related Articles Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: A pilot study. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Rowan CR, Keegan D, Byrne K, Cullen G, Mulcahy HE, Sheridan J, Ryan EJ, de Vries A, D’Haens G, Doherty GA Abstract BACKGROUND: Ustekinumab (USK) is licenced for intravenous induction and subcutaneous (S/C) maintenance in Crohn’s disease. AIM: To evaluate ustekinumab trough concentrations and clinical response with exclusive subcutaneous ustekinumab induction. METHODS: Patients with Crohn’s disease who initiated treatment with subcutaneous…

Read More

Review article: pathogenesis of Crohn’s perianal fistula-understanding factors impacting on success and failure of treatment strategies.

Related Articles Review article: pathogenesis of Crohn’s perianal fistula-understanding factors impacting on success and failure of treatment strategies. Aliment Pharmacol Ther. 2018 Jun 19;: Authors: Tozer PJ, Lung P, Lobo AJ, Sebastian S, Brown SR, Hart AL, Fearnhead N, of ENiGMA Collaboration Abstract BACKGROUND: Evidence from groups who have studied fistula aetiology and extrapolation from interventional studies supports a multifactorial hypothesis of Crohn’s perianal fistula, with several pathophysiological elements that may contribute to fistula formation, persistence and resistance to treatment. AIM: An evidence synthesis of current understanding of pathophysiological factors…

Read More

Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.

Related Articles Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun 14;: Authors: Hanlon I, Hewitt C, Bell K, Phillips A, Mikocka-Walus A Abstract BACKGROUND: Online psychotherapy has been successfully used as supportive treatment in many chronic illnesses. However, there is a lack of evidence on its role in the management of gastrointestinal (GI) diseases. AIMS: To examine whether online psychological interventions improve mental and physical outcomes in gastrointestinal diseases.…

Read More

Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease.

Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun 13;: Authors: van den Brink G, Stapersma L, Vlug LE, Rizopolous D, Bodelier AG, van Wering H, Hurkmans PCWM, Stuyt RJL, Hendriks DM, van der Burg JAT, Utens EMWJ, Escher JC Abstract BACKGROUND: Youths with inflammatory bowel disease (IBD) are at risk for developing anxiety and depressive symptoms with a reported 20%-50% prevalence rate. AIMS: This prospective study aimed to: (1) describe the prevalence and severity…

Read More

Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors’ reply.

Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors’ reply. Aliment Pharmacol Ther. 2018 Jul;48(1):98-99 Authors: Friedman AB, Sparrow MP PMID: 29882984 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29882984?dopt=Abstract

Read More

Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors’ reply.

Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors’ reply. Aliment Pharmacol Ther. 2018 Jun;47(11):1540 Authors: Ungaro R, Colombel JF PMID: 29878427 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29878427?dopt=Abstract

Read More
<< Go Back